eli lilly retatrutide trials Lilly's Delivers Bariatric-Style Weight Loss In Obesity Trial — Stock Rises Pre-Market Lilly's triple agonist achieves 16.8%

Mechanisms differ, and they can be synergistic

What They Are and Why Lifestyle Change Is Key to Sustained Weight Loss

But how do you get it

Key takeaways from TRIUMPH-4 (68 weeks): 28.7% average weight loss at the highest dose 1 in 4 participants lost 35% of body weight ~76% reduction in knee pain Meaningful improvements in BP and lipid markers This pushes weight-loss outcomes closer to bariatric-surgery territory, while also improving joint pain and cardiometabolic risk

Many patients taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) report feeling unusually cold during treatment

The Cleveland Clinic analysis found that many patients who stopped GLP-1 therapy later restarted, sometimes with the same medication, sometimes switching to an alternative